CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma...
Phase 1, Phase 2
Washington, District of Columbia, United States and 2 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Baltimore, Maryland, United States and 89 other locations
and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...
Phase 2
Baltimore, Maryland, United States and 8 other locations
pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...
Phase 1
Baltimore, Maryland, United States and 12 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Baltimore, Maryland, United States and 59 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...
Phase 2
Washington, District of Columbia, United States and 61 other locations
dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...
Phase 1, Phase 2
Washington, District of Columbia, United States and 21 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Fairfax, Virginia, United States and 27 other locations
treatment of advanced classical Hodgkin lymphoma(HL)...
Phase 3
Washington, District of Columbia, United States and 215 other locations
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...
Phase 2
Baltimore, Maryland, United States and 94 other locations
Clinical trials
Research sites
Resources
Legal